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Objectives. To determine whether preoperative portal vein embolisation
improves the operative outcome of patients undergoing extended right-
sided hepatic resection for hepatobiliary malignancy.
Design. Prospective non-randomised study.
Setting. University teaching hospital, Hong Kong.
Patients. Ninety-two patients underwent extended right-sided hepatic
resection for hepatobiliary malignancy during a 45-month period (January
2000 to September 2003). Among them, 15 (16%) underwent portal vein
embolisation via a percutaneous ipsilateral approach (n=9) or through
the ileocolic vein with a mini-laparotomy (n=6). The remaining 77 (84%)
patients underwent hepatic resection without portal vein embolisation.
Main outcome measures. Operative morbidity and mortality.
Results. Patients undergoing portal vein embolisation were older (69 years
vs 55 years; P=0.009), and had significantly worse preoperative renal
function (creatinine, 96 µmol/L vs 86 µmol/L; P=0.039) and liver
function (bilirubin, 23 µmol/L vs 12 µmol/L; P<0.001). Portal vein
embolisation resulted in an increase in the future liver remnant of 9%
(interquartile range, 7-13%) of the estimated standard liver volume. The
operating time for patients receiving portal vein embolisation was
significantly longer (medium, 660 min vs 420 min; P<0.001) with more
complicated surgery performed in terms of concomitant caudate
lobectomy and hepaticojejunostomy. There was no hospital mortality in
patients who underwent portal vein embolisation whereas five without
the treatment died (P=0.587). The operative morbidity of patients who
underwent portal vein embolisation and those who did not was 20% and
30%, respectively (P=0.543).
Conclusions. In older patients who have worse preoperative liver and
renal functions, portal vein embolisation enhances the possibility to
perform extended right-sided hepatic resection for hepatobiliary malig-
nancies with potentially lower operative mortality and morbidity.
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Introduction
Hepatic resection is the treatment of choice for both
primary and metastatic tumours of the liver.1,2 The
safety of surgery has dramatically improved with
better perioperative and intra-operative care in recent
decades. However, major hepatic resection still
carries a substantial risk of mortality and morbidity.
Moreover, there may also be room for improvement
in terms of survival for these patients after major
resection.3 Preoperative portal vein embolisation
(PVE) has been advocated to improve the safety of
major hepatic resection by increasing the volume of
the future liver remnant (FLR).4-6 Although it is
unclear whether PVE affects survival in patients with
hepatocellular carcinoma (HCC),7 it may contribute
to higher safety margins after major hepatic resection
and result in better postoperative outcome, particularly
in cirrhotic patients.4,8 We report the use of preoperative
PVE in patients who underwent extended right-sided
hepatic resection, and investigate whether PVE can
improve the operative outcome.
Methods
A prospective study was performed on all patients who
underwent extended right-sided hepatic resection for
hepatobiliary malignancy between January 2000 and
September 2003 at the Department of Surgery, Queen
Mary Hospital, Hong Kong. Extended right-sided
hepatic resection was defined as right-sided hepatic
resection with more than four Couinaud’s segments,
including right hepatectomy with extension to segment
4, right hepatectomy with caudate lobectomy, and right
trisectionectomy. Preoperative PVE was performed on
patients when hepatectomy comprised more than
70% of the functional hepatic parenchyma without
biliary obstruction, or more than 60% with a history
of biliary obstruction. Patients who underwent
extended right-sided hepatic resection during the
same study period but without prior PVE constituted
the control group.
The percentage of functional hepatic parenchyma
was estimated by volumetry with computed tomog-
raphy (CT). Following administration of intravenous
contrast medium, consecutive transverse scans using
a slice thickness of 3 to 5 mm were used to trace the
tumour and the left, caudate, and right lobe areas of
the liver. If a trisectionectomy was planned, segment
4 area was also traced. The volume of each lobe and
the FLR was calculated by adding the areas of the
consecutive slices. In patients with obstructive jaun-
dice, biliary obstruction was relieved by either percutan-
eous transhepatic biliary drainage or endoscopic
drainage. After the serum total bilirubin level had
dropped to less than 50 µmol/L, PVE was performed
percutaneously by an interventional radiologist using
an ipsilateral approach,9 or by a mini-laparotomy via
the transileocolic vein approach.6 A 5.5 French triple
lumen balloon catheter (Clinical Supply, Nagoya,
Japan) was used for both approaches. A single
surgeon who was responsible for all open PVE with
the transileocolic vein approach was present during
all percutaneous PVEs. The portal anatomy was
studied under direct portal venography with real-time
fluoroscopy to confirm a normal portal blood supply
to the FLR. Portal vein embolisation was then
performed using a mixture of fibrin glue (Beriplast;
Aventis Behring GmbH, Marburg, Germany) and
lipiodol (Lipiodol ultra-fluide; Laboratoire Guerbet,
Aulnay-sous-Bois, France). Injection of the mixture
was stopped when the whole right portal venous
system was obstructed. The balloon was kept inflated
for 3 minutes to prevent accidental embolisation of the
main or left portal venous system. The success of
PVE was then evaluated with fluoroscopy. Patients
were discharged when they were able to walk
independently, usually on the second day after the
procedure. A repeated CT was performed 4 to 6 weeks
after PVE and surgery performed the following week.
Future liver remnant was reassessed by CT
volumetry and the hypertrophy ratio determined by
dividing the post-PVE volume by the pre-PVE volume.
In addition, the standard total liver volume (STLV)
was estimated using the formula devised by Urata
et al,10 and the percentage increase of the FLR as a
Liem et al
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result of PVE relative to the STLV was determined.
Hepatic resection was performed using a standard
technique11,12 and an ultrasonic dissector was used for
parenchymal transection.13,14 All patients received the
same perioperative care by the same team of surgeons
and were treated in the intensive care unit during the
early postoperative period. All intra-operative compli-
cations and postoperative morbidities were recorded
prospectively. Hospital mortality was defined as
death during the same period of hospitalisation for the
hepatic resection.
Clinical data of all patients were recorded prospect-
ively in a computerised database by a single research
assistant. Continuous data were expressed as medians
with their interquartile range. Proportions were given
as number and percentages. Differences between
two groups were assessed with either the Mann-
Whitney U test for continuous data  or the Chi squared
test or Fisher’s exact test where appropriate for
proportions. All reported P values are two-tailed.
A P value of less than 0.05 was considered statis-
tically significant. Statistical analyses were per-
formed using the Statistical Package for the Social
Sciences (Windows version 11.0; SPSS Inc, Chicago
[IL], US).
Results
Between January 2000 and September 2003, 274
(23.6%) of 1162 patients with hepatobiliary malig-
nancy underwent hepatectomy. Ninety-two patients
received extended right-sided hepatic resection, of
whom 15 (16.3%) received preoperative PVE (PVE
group). The remaining 77 patients underwent
resection without prior PVE (non-PVE group). One
patient who had HCC, and in whom preoperative
PVE was performed, was excluded from the present
analysis. Hepatic resection was not performed
because of inadequate hypertrophy of the remnant
liver, thought to be related to underlying liver
cirrhosis. The clinical parameters of both groups
of patients are listed in Table 1. The median age
of the patients in the PVE group was 69 years,
significantly higher than that of the non-PVE group
(55 years, P=0.009). They also had significantly
worse preoperative renal (median serum creatinine,
96 µmol/L vs 86 µmol/L; P=0.039), and liver func-
tions in terms of higher serum alanine aminotrans-
ferase and total bilirubin levels. In addition, there
were significantly more Child-Pugh’s grade15 B
patients in the PVE group than in the non-PVE
group (P<0.001) [Table 1]. These 10 patients were
considered suitable for major hepatic resection
because indocyanine green retention at 15 minutes
was smaller than 16%.1 The pathologies of both groups
of patients are listed in Table 2.
Table 1.  Preoperative clinical and laboratory data of patients who underwent extended right-sided hepatic
resection with preoperative portal vein embolisation (PVE group) and those without (non-PVE group)*
Clinical parameter PVE group Non-PVE group P value
No. of patients 15 77 -
Sex (male:female) 11:4 52:25 <0.768
Age (years) 69 (51-75) 55 (47-64) <0.009
Body weight (kg) 63.8 (58.3-71.2) 56.7 (50.0-69.0) <0.549
Serum albumin (g/L) 37 (36-41) 39 (36-42) <0.534
Serum total bilirubin (µmol/L) 23 (17-33) 12 (9-17) <0.001
Serum creatinine (µmol/L) 96 (85-112) 86 (74-95) <0.039
Alanine aminotransferase (U/L) 54 (46-107) 44 (26-72) <0.048
Haemoglobin (g/L) 129 (110-143) 128 (116-138) <0.857
Prothrombin time (sec) 12.5 (12.0-13.0) 12.6 (11.8-13.1) <0.900
Indocyanine green retention at 15 min (%) 12.1 (10.2-17.2) 10.9 (6.7-14.3) <0.279
Child-Pugh’s grading15 <0.001
QiA 8 (53%) 74 (96%)
QiB 7 (47%) 3 (4%)
* Values are expressed as median (interquartile range), unless otherwise stated
Table 2.  Pathologies of patients with preoperative
portal vein embolisation (PVE group) and those without
(non-PVE group)
Pathology PVE Non-PVE
group, group,
n=15 n=77
Hepatocellular carcinoma 04 (27%) 50 (65%)
Hilar cholangiocarcinoma 10 (67%) 01 (1%)0
Intrahepatic cholangiocarcinoma 00 (67%) 08 (10%)
Combined 11 (7%)0 01 (1%)0
hepatocholangiocarcinoma
Liver metastasis 00 (67%) 13 (17%)
Others* 00 (67%) 04 (5%)0
* Other pathologies included metastatic neuroendocrine tumour
(n=2), rhadomyosarcoma (n=1), and sarcoma (n=1)
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Nine patients received preoperative PVE via a
percutaneous transhepatic ipsilateral approach. The
remaining six underwent diagnostic laparoscopy,
laparoscopic ultrasonography, and mini-laparotomy
with a short lower right paramedian incision. Portal
vein embolisation was performed with the open method
through cannulation of the ileocolic vein. No compli-
cations related to PVE occurred, except for one
patient who developed segmental cholangitis after
the procedure, resulting in a procedure-related
morbidity rate of 6.7%. The complication was prob-
ably related to inadvertent puncture and injection
of contrast to a segmental bile duct obstructed by
hilar cholangiocarcinoma during percutaneous PVE.
The attack of cholangitis subsided after a few days
following treatment with a broad-spectrum antibiotic.
Among the 15 patients in the PVE group, preoperative
PVE achieved a median hypertrophy ratio of 1.26
(range, 1.21-1.36) of the FLR. The percentage increase
in FLR relative to the STLV was 9% (range, 7-13%)
[Table 3].
The extent of hepatic resection in both groups of
patients is listed in Table 4.12 Ten (67%) patients in the
PVE group and 22 (29%) patients in the non-PVE
group underwent caudate lobectomy (P=0.005).
In addition, 11 (73%) patients in the PVE group
underwent concomitant hepaticojejunostomy: this
was significantly more than that in the non-PVE group
(10%, P<0.001). The operating time of the patients
in the PVE group was significantly longer, but the
intra-operative blood loss was comparable (Table 5).
Table 3.  Clinical details of 15 patients who underwent
portal vein embolisation (PVE)*
Clinical details Value
Types of procedure (No. of patients)
QiOpen (through ileocolic vein) 6 (40%)
QiPercutaneous ipsilateral approach 9 (60%)
Time interval between PVE and 37 (32-61)
hepatic resection (days)
Future liver remnant before 411 (360-494)
PVE (mL)
Future liver remnant after PVE (mL) 540 (456-588)
Hypertrophy ratio 1.26 (1.21-1.36)
Standard total liver volume (STLV) 1172 (1110-1258)
[mL]
Increase in future liver remnant after 9 (7-13)
PVE/STLV (%)
* Values are expressed as median (interquartile range), unless
otherwise stated
Table 4.  Extent of hepatic resection in patients with
preoperative portal vein embolisation (PVE group) and
those without (non-PVE group)*
Hepatic resection PVE group, Non-PVE
n=15 group,
n=77
Right hepatectomy+caudate 14 (27%) 15 (7%)3
lobectomy
Right hepatectomy with 13 (20%) 33 (43%)
extension to segment 4
Right hepatectomy with 10 (20%) 16 (8%)3
extension to segment 4+
caudate lobectomy
Right trisectionectomy 12 (13%) 22 (27%)
Right trisectionectomy+ 16 (40%) 11 (14%)
caudate lobectomy
Concomitant 11 (73%) 18 (10%)
hepaticojejunostomy
* The nomenclature of types of hepatic resection was based on
the Brisbane 2000 terminology of liver anatomy and resections12
Table 5.  Intra-operative and postoperative data of patients with preoperative portal vein embolisation (PVE
group) and those without (non-PVE group)*
Intra-operative and postoperative data PVE group, Non-PVE group, P value
n=15 n=77
Intra-operative blood loss (L) 1.43 (1.09-1.80) 1.40 (0.65-2.00) <0.866
Intra-operative blood transfusion (L) 0 0 (0-0.3) <0.344
No. of patients without blood transfusion 12 (80%) 53 (69%) <0.539
Operating time (min) 660 (495-720) 420 (360-555) <0.001
Indocyanine green retention at 15 min on postoperative 21.8 (12.0-39.3) 23.9 (11.7-31.2) <0.693
day 7 (%)
Postoperative stay in intensive care unit (days) 3 (2-4) 1 (1-3) <0.019
Postoperative hospital stay (days) 14 (11-21) 10 (7-14) <0.005
Operative morbidity 3 (20%) 23 (30%).6 <0.543
Hospital mortality 0 05 (6.5%)0 <0.587
* Values are expressed as median (interquartile range), unless otherwise stated
Liem et al
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Sixty-five (70.7%) patients, including 12 patients
in the PVE group and 53 patients in the non-PVE
group, did not require blood transfusion. The median
postoperative intensive care unit and hospital stay of
the patients in the PVE group was 3 days and 14 days,
respectively, and was significantly longer than that
of the non-PVE group (1 day, P=0.019; 10 days,
P=0.005, respectively). The operative morbidity rate
was 20% in the PVE group, and 30% in the non-PVE
group (P=0.543). There was no hospital mortality in
the PVE group, whereas five (6.5%) patients in the
non-PVE group died after hepatic resection (P=0.587).
The causes of hospital mortality were liver failure
(n=3), chest infection (n=1), and intra-abdominal
sepsis (n=1).
Discussion
Preoperative PVE has been advocated for patients who
require major hepatic resection. However, previous
studies16,17 have focused on the technical aspects
such as volume increase, liver function after PVE,
and PVE-related complications. Few report on its
benefits in terms of better operative outcomes
compared with a control group. Azoulay et al18 and
Shimamura et al19 reported comparable complication
rates in HCC patients who received PVE compared
with a control group. Hemming et al4 reviewed
52 patients, of whom 39 had preoperative PVE, and
found a lower incidence of liver failure in the PVE
group. In a prospective non-randomised trial, Farges
et al8 found significantly fewer complications in
patients with cirrhosis who underwent PVE
and right hepatectomy compared with those who
did not undergo PVE. The present study evaluated
the influence of PVE on the early postoperative
outcome for patients who underwent extended
right-sided hepatic resection. There was no hospital
mortality in the PVE group, and the hospital mor-
bidity rate was numerically lower but not statisti-
cally different from that of the non-PVE group,
despite the fact that the former belonged to an older
age-group, had significantly worse preoperative
liver and renal functions, and underwent more
complicated surgery.
There are two major techniques to access the
portal vein for embolisation: direct cannulation of the
ileocolic vein and the percutaneous transhepatic
approach. The former requires a laparotomy under
general anaesthesia in which the ileocolic vein is
cannulated.6 Tumour extent and liver status can be
assessed during the laparotomy with or without prior
laparoscopy. Although the open approach for PVE
may have the disadvantage of requiring a general
anaesthesia and a theoretically higher risk of post-
operative complications, we elected to use an open
approach for PVE via the ileocolic vein in patients
with bulky liver tumours including those with HCC.
By avoiding percutaneous puncture of the liver, the
risk of inadvertently puncturing the tumour leading to
tumour rupture or tumour seeding, and spread of tu-
mour cells through the portal or systemic circulations
could be avoided. In addition, a diagnostic laparoscopy
and laparoscopic ultrasonography performed during
the same anaesthesia may provide accurate staging
of the disease and prevent unnecessary PVE and
laparotomy in patients with unresectable disease.20
In patients with less bulky tumours, and in whom
direct puncture of the portal venous system was
considered feasible on preoperative CT scan, we
adopted the percutaneous ipsilateral approach.9 It has
the advantages of direct access to the portal branches
and a minimal risk of portal vein thrombosis and
inadvertent vascular injury to the FLR. We did not use
a contralateral percutaneous approach in any of the
patients in the present series, as this technique may
lead to vascular injury of the FLR, and bleeding will
not be controlled by PVE of the contralateral side as
opposed to the ipsilateral approach.
There has been a wide range of preference in the
use of embolic materials for preoperative PVE,
including cyanoacrylate and ethiodised oil, Gelfoam
(Upjohn, Kalamazoo[MI], US) and thrombin, fibrin
glue, metallic coils, polyvinyl alcohol, and absolute
alcohol. Cyanoacrylate has been recommended as
the best substance for PVE as it leads to fast and
reliable hypertrophy of the FLR.21 However, it may
cause a severe inflammatory reaction with peribiliary
fibrosis and casting of the portal vein, leading to
increased operative difficulty. Nagino et al22 advocated
the use of fibrin glue for PVE. Although the re-
canalisation rate may be higher, fibrin glue appeared
to be safe and effective without the complication of
extensive inflammatory fibrosis. Following the
experience of Nagoya,23 fibrin glue was used for
PVE in all patients in the present study. The extent
of hypertrophy of FLR of our patients fell within a
range comparable with that reported by others.8,16
In addition, none of the patients in the PVE group
developed liver failure or had hospital mortality,
suggesting that the rate of hypertrophy achieved as a
result of PVE was sufficient for the patients to undergo
extended hepatic resection. It has been suggested
that PVE may result in a more difficult resection.4 It is
possible that the use of fibrin glue as embolic material
in this series meant that we experienced no increased
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difficulty in both hilar dissection or parenchymal
transection in patients who had preoperative PVE
compared with those without the procedure.
An interesting finding was the satisfactory increase
in the size of FLR after preoperative PVE, although
the median age of PVE group was 69 years. This
suggests that PVE is effective in inducing hypertro-
phy of FLR in elderly patients. Since elderly patients
may have reduced functional reserves of the
cardiovascular system, respiratory system, or kidney
that may result in increased risks of morbidity and
mortality after major hepatic resection, preoperative
PVE may be particularly useful by providing
adequate liver reserve compared with the younger
patients.
Although PVE appears to be a safe and effective
procedure with no mortality or major morbidity
reported in the literature, complications including
recanalisation of the portal vein,24 haemobilia,25 and
small bowel obstruction17 have been encountered. In
the limited experience of this study, only one patient
developed a procedure-related complication of
segmental cholangitis. There is a theoretical risk of
promoting tumour growth by PVE especially in pa-
tients with colorectal liver metastases.26,27 Nonetheless,
subsequent studies28,29 have shown an equivalent
survival between standard resection patients and
patients who undergo preoperative PVE. There is
no evidence to suggest that PVE can induce tumour
growth in patients with HCC and other hepatobiliary
malignancies including cholangiocarcinoma, and we
experienced no accelerated tumour growth after PVE
in this study. Regrettably this study could not identify
the group of patients who would benefit most from
PVE. The evidence that supports the use of preoperative
PVE can only be derived from prospective compari-
son series and inference from PVE series with
previously reported studies that describe the results
of hepatic resection without PVE. Future prospective
randomised studies should be conducted to verify
the benefits and efficacy of preoperative PVE in
patients with hepatobiliary malignancy and to better
identify patients who will benefit from the procedure.
Other limitations of the present study included the
presence of heterogeneous hepatobiliary malignancies
and a relatively small number of patients in the
study group. Nevertheless, this study represented
the initial local experience of the procedure. With
improved understanding of the technique and
indications for the procedure, the number of patients
undergoing preoperative PVE for various indications
has increased in recent years. In future, prospective
evaluation of a specific group of patients including
patients with HCC will be performed.
Conclusions
Preoperative PVE increases the possibility to perform
extended right-sided hepatic resection for hepatobiliary
malignancy in older patients with worse renal and
hepatic functions, without increasing operative blood
loss, morbidity, or mortality. Portal vein embolisation
is a useful technique to extend the limits of hepatic
resection. Future studies, possibly randomised
controlled trials, should further define its precise
indication.
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